Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The system was built with patients in mind, and its compact design has the potential to expand access to the modality where it may have previously been lacking.
The San Francisco-based company says the updates will accelerate radiology workflows by removing administrative burdens and freeing up radiologists to spend more time reviewing imaging exams instead.
The method targets cancer stem cells, which are highly tumorigenic and known to play a significant role in relapse, cancer spread and treatment resistance.
In the study, patients who had recovered from an COVID infection were injected with a small amount of the 89Zr-labeled radiotracer before undergoing a uExplorer PET/CT scan.
A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.
A clinical trial pitting MRI against a burgeoning PET/CT technique has found the de facto defending champion better at revealing the presence of any grade of prostate cancer.
One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality.
PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam.
This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients.